Asthma
- Aerobics Cardio
- Asthma
- Back Pain
- Blood Cancer
- Breast Canser
- Cancer
- Cholestrol
- Dental
- Depression
- Diabties
- Diet
- Drinks
- Drug
- Exercise
- Fastfood
- Fitness
- Health
- Health Care
- Heart Disease
- Home Remedies
- Hypertension
- Injury
- Massage
- Medical Services
- Medicine
- Men Health
- Mental Health
- News
- Skin Care
- Supplements
- Treatments
- Weight Loss
- Women Health
- Yoga
Enjoying our content?
Subscribe and receive a weekly newsletter packed with awesome stories to inspire you!
Asthma
Back to highschool asthma’ related to attacks spike
CHILDREN are more likely to need to peer a health practitioner for bronchial asthma attacks at the beginning of the college year, new studies indicate. Figures display that the number of appointments related to "lower...
Asthma
IgE Reactivity to Cockroach Varies
Immunoglobulin E (IgE) reactivity varies appreciably with allergies and rhinitis in hypersensitive reactions to cockroaches, in step with a look at outcomes published in The Journal of Allergy and Clinical Immunology. IgE sensitivity profiles and...
Asthma
Fat collects in lungs of obese people, elevating asthma hazard
Excess weight is hard at the coronary heart, but new research indicates it can also damage your lungs. The study found that better quantities of fats collect in the airways of overweight and overweight human...
Asthma
Fat Collects in Lungs, Raising Asthma Risk
FRIDAY, Oct. 18, 2019 (HealthDay News) -- Excess weight is hard at heart; however, new studies suggest it can also damage your lungs. The observe discovered that better quantities of fats acquire inside overweight and...
Asthma
Asthma and Ultra-Processed Food in Childhood
According to an examination published in Pediatric Allergy and Immunology, there isn't any affiliation between the consumption of extremely‐processed meals (UPF) in childhood and an elevated danger of developing wheeze or allergies in adolescence. Researchers...
Asthma
Upcoming events – Novartis’s bronchial asthma Zeal and Alnylam’s lumasiran test
Welcome to your weekly roundup of drawing close medical readouts. Novartis will record the primary section III statistics with fevipiprant, an oral DP2 inhibitor, in extreme bronchial asthma in the fourth region. The agency hopes...